Maxwell Biomedical

Maxwell Biomedical is pioneering a paradigm shift in atrial fibrillation treatment with its Rhythm360 system and CRT-A therapy. Unlike current ablative or pharmacologic rhythm control strategies, CRT-A aims to resynchronize atrial activation to restore the heart's natural pumping mechanics without destroying tissue, targeting the unmet need of atrial dysfunction in AF-HFpEF patients. The company, led by a seasoned medtech team, is in the development stage, having recently secured a new financing round to advance its technology. Its approach represents a potential new class of therapy that could improve hemodynamics and outcomes for large patient populations currently lacking adequate device solutions.

The Rhythm360 system enabling Cardiac Resynchronization Therapy for the Atrium (CRT-A). It combines advanced inter-cardiac monitoring to detect AF triggers with non-destructive Sinus Rhythm Therapy (SRT) designed to resynchronize atrial activation and restore mechanical pump function.

CRT-A faces no direct competitors, as it defines a new therapy class. However, it competes indirectly with the entire AF treatment ecosystem: catheter ablation systems (e.g., from Johnson & Johnson, Medtronic, Boston Scientific), anti-arrhythmic drugs, and left atrial appendage closure devices. Its value proposition must demonstrate superiority in improving atrial function and hard clinical outcomes beyond what these established, symptom-focused therapies provide.